Cue Biopharma Stock Total Asset
| CUE Stock | USD 1.02 0.01 0.97% |
Cue Biopharma fundamentals help investors to digest information that contributes to Cue Biopharma's financial success or failures. It also enables traders to predict the movement of Cue Stock. The fundamental analysis module provides a way to measure Cue Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cue Biopharma stock.
Cue |
Cue Biopharma Company Total Asset Analysis
Cue Biopharma's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Cue Biopharma Total Asset | 61.53 M |
Most of Cue Biopharma's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cue Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Based on the latest financial disclosure, Cue Biopharma has a Total Asset of 61.53 M. This is 99.18% lower than that of the Biotechnology sector and 96.89% lower than that of the Health Care industry. The total asset for all United States stocks is 99.79% higher than that of the company.
Cue Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cue Biopharma's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics of similar companies.Cue Biopharma is currently under evaluation in total asset category among its peers.
Cue Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.91) % | ||||
| Current Valuation | 46.14 M | ||||
| Shares Outstanding | 63.35 M | ||||
| Shares Owned By Insiders | 0.54 % | ||||
| Shares Owned By Institutions | 23.59 % | ||||
| Number Of Shares Shorted | 1.78 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.72 X | ||||
| Price To Sales | 7.87 X | ||||
| Revenue | 5.49 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (50.73 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 14.7 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (39.96 M) | ||||
| Short Ratio | 1.54 X | ||||
| Earnings Per Share | (0.91) X | ||||
| Target Price | 3.6 | ||||
| Number Of Employees | 53 | ||||
| Beta | 1.8 | ||||
| Market Capitalization | 65.25 M | ||||
| Total Asset | 61.53 M | ||||
| Retained Earnings | (301.19 M) | ||||
| Working Capital | 34.37 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
| Net Asset | 61.53 M |
About Cue Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cue Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cue Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cue Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:Check out Cue Biopharma Piotroski F Score and Cue Biopharma Altman Z Score analysis. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.